Igor Puzanov Selected Research

Chills

10/2018	Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
9/2017	Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
9/2015	Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Igor Puzanov Research Topics

Disease

98	Melanoma (Melanoma, Malignant) 12/2023 - 04/2006
95	Neoplasms (Cancer) 03/2024 - 04/2006
26	Renal Cell Carcinoma (Grawitz Tumor) 01/2023 - 01/2007
17	Disease Progression 02/2023 - 08/2010
10	Fatigue 10/2018 - 05/2012
8	Brain Neoplasms (Brain Tumor) 10/2022 - 05/2012
7	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2024 - 08/2015
6	Neoplasm Metastasis (Metastasis) 02/2024 - 05/2012
6	Hypertension (High Blood Pressure) 01/2018 - 05/2009
5	Prostatic Neoplasms (Prostate Cancer) 02/2024 - 01/2018
5	Cardiotoxicity 01/2022 - 02/2009
5	Colitis 12/2021 - 02/2014
5	Exanthema (Rash) 05/2016 - 05/2012
5	Neutropenia 12/2015 - 06/2012
4	COVID-19 02/2024 - 01/2021
4	Myocarditis (Carditis) 01/2022 - 11/2016
4	Fever (Fevers) 09/2017 - 11/2012
4	Thrombocytopenia (Thrombopenia) 01/2017 - 06/2012
4	Hand-Foot Syndrome 05/2016 - 05/2009
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 01/2012
3	Chills 10/2018 - 09/2015
3	Ovarian Neoplasms (Ovarian Cancer) 08/2015 - 06/2011
2	Lung Neoplasms (Lung Cancer) 02/2024 - 11/2023
2	Merkel Cell Carcinoma 01/2022 - 01/2018
2	Hypophysitis 12/2021 - 05/2015
2	Neurologic Manifestations (Neurological Manifestations) 11/2021 - 08/2018
2	Urinary Bladder Neoplasms (Bladder Cancer) 11/2020 - 11/2016
2	Endometrial Neoplasms (Endometrial Cancer) 11/2020 - 08/2017
2	Primitive Neuroectodermal Tumors (PNET) 01/2020 - 12/2009
2	Diarrhea 10/2018 - 02/2014
2	Erdheim-Chester Disease 03/2018 - 08/2015
2	Langerhans-Cell Histiocytosis (Histiocytosis, Langerhans Cell) 03/2018 - 08/2015
2	Multiple Myeloma 01/2018 - 01/2017

Drug/Important Bio-Agent (IBA)

26	Immune Checkpoint InhibitorsIBA 03/2024 - 05/2015
23	IpilimumabIBA 01/2023 - 05/2012
22	Biomarkers (Surrogate Marker)IBA 10/2023 - 01/2010
18	pembrolizumabIBA 01/2023 - 08/2015
18	VemurafenibIBA 01/2020 - 08/2010
12	talimogene laherparepvecIBA 01/2023 - 01/2015
11	NivolumabIBA 02/2023 - 04/2014
11	Sunitinib (Sutent)FDA Link 10/2021 - 09/2008
10	LigandsIBA 02/2024 - 11/2015
10	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2021 - 01/2007
9	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2023 - 01/2012
8	AntibodiesIBA 01/2020 - 06/2013
8	Sorafenib (BAY 43-9006)FDA Link 06/2017 - 05/2008
6	Monoclonal AntibodiesIBA 01/2020 - 12/2011
6	Phosphotransferases (Kinase)IBA 03/2018 - 09/2008
5	Everolimus FDA Link 01/2023 - 03/2016
4	Interleukin-2 (IL2)IBA 02/2024 - 02/2009
4	dabrafenibIBA 09/2023 - 11/2012
4	Chimeric Antigen ReceptorsIBA 01/2023 - 11/2016
4	AntigensIBA 10/2022 - 11/2018
4	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2022 - 05/2015
4	SteroidsIBA 01/2022 - 01/2017
4	Proteins (Proteins, Gene)FDA Link 01/2020 - 12/2011
4	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2018 - 05/2012
4	Bevacizumab (Avastin)FDA Link 01/2016 - 05/2009
4	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 02/2012 - 05/2010
3	Androgen Receptors (Androgen Receptor)IBA 03/2023 - 01/2018
3	B7-H1 AntigenIBA 01/2023 - 08/2017
3	Mitogen-Activated Protein KinasesIBA 10/2022 - 09/2010
3	Alanine Transaminase (SGPT)IBA 12/2021 - 02/2015
3	Axitinib (AG 013736)IBA 01/2021 - 01/2018
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021 - 11/2016
3	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2020 - 01/2015
3	CTLA-4 AntigenIBA 01/2017 - 11/2014
3	Cetuximab (Erbitux)FDA Link 08/2015 - 12/2011
3	Gemcitabine FDA Link 08/2015 - 06/2012
3	ganitumabIBA 06/2012 - 12/2009
2	Folic Acid (Vitamin M)FDA LinkGeneric 02/2024 - 11/2023
2	Tyrosine Kinase InhibitorsIBA 01/2023 - 01/2022
2	tilsotolimodIBA 12/2022 - 01/2021
2	TroponinIBA 01/2022 - 01/2021
2	PlatinumIBA 01/2022 - 01/2012
2	Macrophage Colony-Stimulating FactorIBA 01/2022 - 07/2015
2	pexidartinibIBA 01/2022 - 07/2015
2	angiokinesIBA 06/2021 - 01/2021
2	Troponin IIBA 01/2021 - 01/2019
2	Toll-Like Receptor 9IBA 01/2021 - 01/2020
2	cobimetinibIBA 01/2020 - 08/2014
2	Proto-Oncogene Proteins B-rafIBA 01/2018 - 09/2010
2	ARQ 197IBA 01/2018 - 02/2015
2	Formaldehyde (Formol)FDA Link 01/2018 - 01/2017
2	ParaffinIBA 01/2018 - 01/2017
2	Codon (Codons)IBA 12/2017 - 04/2015
2	CytokinesIBA 11/2016 - 11/2013
2	Blocking AntibodiesIBA 11/2016 - 11/2015
2	trametinibIBA 03/2016 - 11/2012

Therapy/Procedure

86	Therapeutics 10/2023 - 04/2006
33	Immunotherapy 03/2024 - 05/2010
15	Drug Therapy (Chemotherapy) 03/2024 - 04/2006
5	Aftercare (After-Treatment) 02/2023 - 12/2011
5	Radiotherapy 01/2020 - 05/2015
3	Cell- and Tissue-Based Therapy (Cell Therapy) 02/2024 - 10/2022
3	Precision Medicine 01/2022 - 11/2016
3	Injections 10/2018 - 01/2015
2	Castration 03/2023 - 01/2018
2	Lymph Node Excision (Lymph Node Dissection) 10/2022 - 01/2018
2	Duration of Therapy 01/2022 - 08/2015